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Abstract
Background—Data from prospective cohort studies regarding the association between
ambulatory heart rate (HR) and cardiovascular events (CVE) are conflicting.
Methods—To investigate whether ambulatory HR predicts CVE in hypertension, we performed
24-hour ambulatory blood pressure and HR monitoring in 7600 hypertensive patients aged 52±16
years from Italy, U.S.A., Japan, and Australia, included in the ‘ABP-International’ registry. All
were untreated at baseline examination. Standardized hazard ratios for ambulatory HRs were
computed, stratifying for cohort, and adjusting for age, gender, blood pressure, smoking, diabetes,
serum total cholesterol and serum creatinine.
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Results—During a median follow-up of 5.0 years there were 639 fatal and nonfatal CVE. In a
multivariable Cox model, night-time HR predicted fatal combined with nonfatal CVE more
closely than 24h HR (p=0.007 and =0.03, respectively). Daytime HR and the night:day HR ratio
were not associated with CVE (p=0.07 and =0.18, respectively). The hazard ratio of the fatal
combined with nonfatal CVE for a 10-beats/min increment of the night-time HR was 1.13 (95%
CI, 1.04–1.22). This relationship remained significant when subjects taking beta-blockers during
the follow-up (hazard ratio, 1.15; 95% CI, 1.05–1.25) or subjects who had an event within 5 years
after enrollment (hazard ratio, 1.23; 95% CI, 1.05–1.45) were excluded from analysis.
Conclusions—At variance with previous data obtained from general populations, ambulatory
HR added to the risk stratification for fatal combined with nonfatal CVE in the hypertensive
patients from the ABP-International study. Night-time HR was a better predictor of CVE than
daytime HR.
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INTRODUCTION
Several studies have demonstrated an association between resting heart rate (HR) and
cardiovascular mortality both in general populations (1–3) and in patients with hypertension
(4,5) or cardiac diseases (6,7). However, a few HR readings taken in a clinic environment
might be poorly representative of the actual HR levels leading to an underestimation of their
real predictive power. HR assessed out of the office in association with ambulatory blood
pressure is more representative of a subject’s usual HR and offers additional information
about the HR circadian pattern, including HR during the sleep period. Several studies have
specifically explored the association between ambulatory HR and fatal and nonfatal
cardiovascular events (CVE) but the evidence relating outcome to ambulatory HR remains
incomplete and lacks consistency (8–14). Most investigators reported only on fatal
outcomes, with night-time HR or a blunted fall in HR at night predicting all-cause mortality
in some of these studies (8,9,12,13). HR nondipping predicted CVE in one study (14). In
keeping with what was observed with ambulatory blood pressure (15), these results suggest
that HR during sleep, or the day–night HR dip might have better predictive power than
daytime HR. The few studies that reported information on CVE failed to demonstrate an
independent association between ambulatory HR and cardiovascular outcomes either in
general populations (12,13) or in hypertensive patients (8). Establishing the predictive value
of ambulatory HR for CVE in hypertension would have important therapeutic implications
because antihypertensive drugs with cardiac slowing properties may exert an additional
benefit in patients with high HR.
The “Ambulatory Blood Pressure in referred hypertensive subjects: an International
database” (ABP-International) is an international consortium composed of normotensive and
hypertensive subjects assessed with 24-hour ambulatory blood pressure and HR
measurement. The aim of the current study was to explore the relationship between
ambulatory HR at baseline and fatal combined with nonfatal CVE in this international
database and to investigate the relationship between 24-hour, daytime, and night-time HR
and CVE in the 7600 hypertensive patients from this database.
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The ABP-International study is an international registry established in order to investigate
the relationship of 24-hour ambulatory blood pressure and HR with morbidity and mortality
in a large patient population recruited in different centers around the world. The database
was constructed by systematically merging 8 prospective studies from 3 European, 3
Japanese, 1 North American, and 1 Australian centers. Although protocols were not
standardized, studies were conducted following similar procedures and were eligible for
inclusion if they involved a random population sample or patients referred to hospital for
hypertension, if baseline information on ambulatory blood pressure and HR and
cardiovascular risk factors was available, and if the follow-up included fatal and nonfatal
CVE. The above information was provided by the investigators in electronic format. For the
present analysis, we selected untreated participants in which office and ambulatory HRs
were available and office blood pressure was in the hypertensive range (≥ 140 mmHg
systolic or ≥ 90 mmHg diastolic). Thus, 3635 subjects were excluded because of missing
data on relevant variables, antihypertensive treatment at baseline, or office blood pressure <
140/90 mmHg (figure 1) leaving 6 cohorts (office HR and/or ambulatory HR not available
in the Ohasama study and the American Study) and 7600 participants for analysis. Thus, the
present analysis included 2942 participants from the PIUMA study, Italy (16), 671 patients
from the Jichi School of Medicine, Japan (17), 1859 patients from the University of Chieti,
Italy (18), 664 participants from the ANBP2 study, Australia (19), 346 patients from one
clinic and two hospitals in the Karatsu-Nishiarita Study, Japan (20), and 1118 participants
from the HARVEST study, Italy (21). Study protocols were approved by the local Ethics
Committees and informed consent was obtained from all of the participants. The study
procedures were conducted in accordance with the ethical guidelines of the 1975
Declaration of Helsinki and the local institutional guidelines.
Blood pressure and heart rate measurements
Office blood pressure was measured by trained observers using a standard auscultatory
method and was the mean of 2 to 6 readings. Office HR was measured from pulse palpation
over ≥15 seconds, ranging from 15 to 60 seconds, and was the mean of 1 to 3 measurements.
For ambulatory monitoring, validated monitors were programmed to obtain ambulatory
blood pressure and HR readings at intervals ranging from 10 to 30 minutes during daytime
and from 15 to 30 minutes at night. Participant’s awake (or daytime) and asleep (or night-
time) periods were determined from the diary sheet in 5 cohorts (mean±SD for night-time,
7.1±1.7 hours) and was the interval between 7:00 AM and 11:00 PM and between 11:00 PM
and 7:00 AM, respectively, in one study (21). Within individual subjects, the arithmetic
average of the 24-hour, daytime and night-time periods were used as the ambulatory
measurements. Daytime blood pressure and HR were calculated from an average of
71.3±22.5 readings and night-time blood pressure and HR from an average of 16.5±4.0
readings. The nocturnal fall in blood pressure and HR was computed from the night:day
ratio.
Procedures
Each patient’s medical history including intake of medications, and information on smoking
and alcohol consumption was collected through questionnaires originally administered in
each cohort (22). Current smokers were those who reported smoking one or more cigarettes
per day. Alcohol intake was calculated by summing the total number of milliliters of alcohol
consumed as wine, beer, and spirits. Subjects were then categorized as nondrinkers (class 0),
light drinkers (class 1), moderate drinkers (class 2), and heavy drinkers (class 3). Body mass
index was body weight in kilograms divided by height in meters squared. Serum creatinine,
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total cholesterol and blood glucose concentrations were measured by automated enzymatic
methods. Diabetes mellitus was defined as a self reported diagnosis, the use of antidiabetic
drugs, a fasting blood glucose concentration of at least 7.0 mmol/l, or a random blood
glucose concentration of at least 11.1 mmol/l. Having diabetes was scored 1 and the absence
of diabetes was scored 0.
The observation period was considered as the number of years from the first available 24-
hour recording to the date of the last clinical visit or the first endpoint. Information on type
of antihypertensive treatment taken during the follow-up was collected. The primary
endpoint was a composite of all fatal and first nonfatal CVE. In all outcome analyses, we
considered only the first event within each category.
Definition of cardiovascular events
Cardiovascular events included fatal and nonfatal acute myocardial infarction, sudden
cardiac death, new-onset heart failure needing at least hospitalization, death from
progressive heart failure or other cardiovascular causes, any myocardial revascularization
procedure, fatal and nonfatal strokes, any aortic or lower limb revascularization procedure.
Nonfatal stroke did not include transient ischemic attack. We ascertained vital status and the
incidence of fatal and nonfatal events from medical records, death certificates and interviews
with attending physicians and patient’s families.
Statistical Methods
Statistical analysis was carried out using SYSTAT version 10 and version 11 (SPSS Inc.,
Chicago, IL, USA), and SAS 9.3 (SAS Institute Inc., Cary, NC, USA) packages. Differences
in mean values were tested with an unpaired Student t test. Variables significantly associated
with HR in univariate correlation analysis were entered as independent variables in a linear
multiple regression analysis predicting HR. The associations between HR and time to CVE
were analyzed using the Cox proportional hazards regression model. All Cox models were
stratified by Center. In addition, since patients within the same site may share similar hidden
risk factors, we used Cox proportional hazards models with shared frailty, where cluster
effects were incorporated into the models as an independent and identically distributed (in
our case gamma distributed) random variable (23). The hazard ratios of the univariate and
multivariable analyses and corresponding two-sided 95% confidence intervals were derived
from the regression coefficients in the Cox models. Hazard ratios were adjusted for age,
BMI, blood pressure, and total serum cholesterol and creatinine concentrations, which were
fitted as continuous variables, and for gender, smoking, alcohol intake and diabetes, which
were fitted as categorical variables. Adjusted models for the night:day HR ratio additionally
included the corresponding night:day systolic blood pressure ratio and average 24-hour HR.
All available risk factors were entered into a first model. A parsimonious set of covariates
was selected using sequential backward elimination of the least significant variables.
Subsequently, a final model was developed in which the HR was entered as the first variable
and then was adjusted for all the other variables that were found to be significant (final
parsimonious model). To compare non-nested models, we used the Akaike Information
Criteria (AIC) and the Schwarz’s Bayesian Information Criterion (BIC) (24,25). For both
AIC and BIC criteria, the model providing smallest values is considered to have the best fit
(24,25). In addition, a measure that can be used to compare survival models is the delta AIC
(Δi). This is a measure of each model AIC relative to the model with the smallest AIC. As a
rule for interpretation, a Δi < 2 suggests substantial evidence for the model, values between
3 and 7 indicate that the model has considerably less support, whereas a Δ i > 10 indicates
that the model is very unlikely (26). The risk of cardiovascular events as a function of night-
time HR was tested in relation to night-time systolic blood pressure in the subjects stratified
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by gender. In this analysis, night-time HR was represented by four risk functions
corresponding to levels of 55, 62, 68, and 77 beats/min (midpoints within each HR quartile).
Analyses were performed using a significance level of α=.05 (2-sided). To ensure the
robustness of the present findings, 4 sensitivity analyses were performed, excluding subjects
who experienced an event within 1, 2, 3, and 5 years of enrollment. As medication with
beta-blockers may influence HR during the follow-up, we also made an analysis after
excluding the 996 patients known to be taking beta-blockers after baseline assessment. In all
outcome analyses only the first event was considered.
RESULTS
The study population consisted of 3435 women (45.2%) and 4165 men (54.8%). Of these,
6583 were Caucasians (86.6%) and 1017 were Asians (13.4%). None of the subjects
considered for this analysis had atrial fibrillation or other relevant arrhythmias at baseline
assessment. At enrollment, 1556 participants (20.5%) were current smokers, and 608 (8.0%)
were diabetics. Mean age ± SD was 52.4±15.8 years, office systolic blood pressure was
155.7±16.5 mm Hg, diastolic BP was 95.0±9.5 mm Hg, and body mass index (BMI) was
26.2±3.9 kg/m2. Office HR (76.4±11.1 bpm) was higher than average 24-hour HR (73.7±8.8
beats/min). Ambulatory HR averaged 77.4±9.4 and 65.5±9.0 beats/min during daytime and
night-time, respectively. Age-adjusted night-time HR was higher in women than men
(67.2±8.9 vs 64.1±8.9 beats/min, p<0.001), in smokers than non smokers (67.0±9.7 vs
65.1±8.8 beats/min, p<0.001), and in diabetic than non diabetic patients (66.9±8.9 vs
65.3±10.1 beats/min, p<0.001). In simple regression analyses, the night-time HR showed
significant associations with age (negative), BMI, night-time systolic and diastolic blood
pressures, glucose, total cholesterol, and creatinine (all p<0.001). In the subsequent
multivariable analysis, the nighttime HR was negatively associated with age (p<0.001) and
was positively associated with female gender, BMI, night-time systolic or diastolic blood
pressure, glucose, cholesterol, diabetes, and smoking (all p<0.001).
Cardiovascular events
During a median follow-up of 5.0 years (interquartile range, 3.5–8.4 years), there were 625
fatal plus nonfatal CVE and 14 cases with end-stage renal disease. Considering cause-
specific first CVE, the incidence of fatal and nonfatal stroke amounted to 37 and 222,
respectively. Cardiac events included 18 fatal and 145 nonfatal cases of acute myocardial
infarction, 25 sudden deaths, 10 deaths from other cardiovascular causes, 59 cases of heart
failure requiring hospitalization, 64 cases of surgical or percutaneous coronary
revascularization, and 45 cases of peripheral vascular disease.
Risk associated with increased heart rate
In Cox models adjusted for age and sex and stratified by Center, a 10 beats/min increase in
each of the baseline ambulatory HR measures was significantly associated with increased
CVE risk (table 1). Among the ambulatory HRs, the risk of CVE was higher for night-time
HR than for 24-hour HR or daytime HR. Night-time HR consistently predicted cardiac
events (p=0.001), fatal and nonfatal myocardial infarction (p=0.032), and fatal and nonfatal
stroke (p=0.002). Office HR was a weaker predictor of outcome than the ambulatory HRs.
Inclusion of systolic and diastolic blood pressures as covariates in the model attenuated the
relationship of the ambulatory HRs with CVE and office HR was no longer a significant
predictor of outcome in this model (table 1). All ambulatory systolic blood pressures and
office systolic blood pressure were strong predictors of outcome (p<0.001) whereas all
diastolic blood pressures were not accepted in the models. BMI (p=0.70) and alcohol
consumption (p=0.45) were other variables not accepted in the models and were not
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included in the final parsimonious models. The multivariate-adjusted hazard ratios for CVE
associated with a 10 beats/min increase in the ambulatory HRs are shown in table 1. In these
models, night-time HR and 24-hour HR remained significant predictors of outcome while
the association was no longer significant for daytime HR. The model including night-time
HR had the smallest AIC, and neither the model including daytime HR nor that including
24-hour HR had a Δ i < 2 (table 2). Compared to the basic model with covariates, BIC was
higher for either model including daytime HR or 24-hour HR, while the model including
night-time HR had the smallest BIC (table 2) lending further support to the latter as being
the most informative model. After further adjustment for beta-blocker treatment the p-value
for night-time HR was 0.006. Including a random frailty term in the survival models had
little effect on risk estimates and statistical significance of the fixed effects (for 10 bpm
increase night-time HR the adjusted hazard ratio was 1.14 and 95%CI, 1.04–1.25; p=0.004)
with a very low estimated variance of the random effect (theta=0.09) corresponding to a
Kendall’s Tau of 0.043 (a global measure of dependence; values interpreted as 0=no
correlation; 1=maximum correlation), which reveals a likely negligible dependence. Night-
time HR (p=0.040) but not 24-hour HR (p=0.16) or daytime HR (p=0.27) remained a
significant predictor of outcome also when office HR was forced in the Cox model. The
night:day ratio of HR was a significant predictor of CVE after adjustment for age, sex, and
average 24-hour HR (table 1). However, when average 24-hour systolic blood pressure and
the night:day ratio of systolic blood pressure were included in the Cox model this
association was no longer significant. Night-time HR remained a significant predictor of
outcome in a sensitivity analysis from which we excluded patients who were treated with
beta-blockers during the follow-up (table 3). In contrast with the overall result, no
relationship between night-time HR and cardiovascular outcomes was found within the 996
patients on beta-blockers (hazard ratio,1.00 and 95%CI, 0.97–1.03; p=0.96). The strength of
the association between night-time HR and CVE remained consistent or even increased
when we excluded subjects who experienced an event within 1 to 5 years of enrollment
(figure 2). Figure 3 shows the independent multivariate-adjusted associations of CVE with
night-time systolic blood pressure and night-time HR by gender. The risk of CVE
progressively increased with increasing systolic blood pressure and HR in both genders
without interaction between sex, systolic blood pressure and HR (p=0.82).
DISCUSSION
The present analysis relating to a cohort of untreated hypertensive patients from the ABP-
International database has demonstrated an independent association of ambulatory HR with
fatal combined with nonfatal CVE in these patients. This relationship was linear and similar
in the two genders. Among the ambulatory HRs, the model including night-time HR was
more informative in predicting the outcome than models with daytime or 24-hour HR. For
every 10-beats/min increment in night-time HR, the adjusted risk of CVE increased by 13%.
Previous studies
HR measured at rest in the clinic (1–7) or at home (27) has been shown to be an important
predictor of adverse cardiovascular outcomes in previous studies. Much less is known about
the predictive power of HR recorded over the 24 hours. Results from two general population
studies have shown that neither daytime nor night-time HR predicted cardiovascular disease
mortality (12,13). However, in the Ohasama study ambulatory HR predicted
noncardiovascular disease mortality (12). In a recent analysis of 6 general population
studies, 24-hour HR predicted total and noncardiovascular mortality but neither
cardiovascular mortality nor any of the fatal combined with nonfatal CVE (13). Previous
studies have shown that the predictive power of elevated office HR for cardiovascular
disease is greater in hypertensive than in normotensive subjects suggesting that HR and
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blood pressure may act synergistically in the development of CVE (28,29). To our
knowledge, the prognostic significance of ambulatory HR in hypertensive patients has been
evaluated in four previous studies. In 393 elderly patients with isolated systolic hypertension
and 457 Japanese hypertensives, no independent association of average ambulatory HRs
with cardiovascular outcomes was found (9,14). Also in a study by Verdecchia et al in 1942
untreated hypertensive patients ambulatory HR was unrelated to combined fatal and nonfatal
CVE (8). Finally, in 3957 referred patients, 50% of whom were on antihypertensive
treatment, Ben-Dov et al found that nocturnal HR but not daytime HR was associated with
total mortality (11). Unfortunately, in the Ben-Dov et al study no information was available
about CVE.
The present study
The present results were obtained in the largest ever study of hypertensive patients assessed
with ambulatory HR monitoring. All patients were untreated at the time of baseline
assessment thereby avoiding the confounding effect of HR lowering drugs. However,
pharmacological manipulation of HR during the follow-up might have altered the
relationship between baseline HR and outcome (30). For this reason we repeated the Cox
analysis after excluding the 996 subjects taking beta-blockers during the follow-up period
obtaining consistent results, with an adjusted increase in CVE risk of 15% per 10-beats/min
increment in night-time HR. In contrast with this finding, within the subjects taking beta-
blockers during the follow-up period no relation at all was found between night-time HR
and cardiovascular outcomes (p=0.96) indicating that after pharmacological HR reduction
the association of pre-treatment HR with subsequent CVE can be lost.
In the present study, among the ambulatory HRs, night-time HR showed a better predictive
value than daytime HR. This finding is in keeping with previous data by others which
showed that high HR during the night-time but not during waking hours was associated with
increased noncardiovascular mortality (12,13) and raises the question about the
pathophysiological significance of elevated HR during sleep.
Mechanisms
A possible mechanism by which a fast HR might relate to CVE is through increased
sympathetic tone having adverse hemodynamic effects which might accelerate
atherosclerosis (31–34). HR during sleep is more stable and reproducible than HR during
waking hours which is subject to random fluctuations related to physical activities and
occasional emotional triggers. Daytime HR may be less reproducible also across different
centers because of the differing procedures used during the recordings (standardized versus
non-standardized activities). In a study by Perski et al on the relationship between
ambulatory HR and coronary atherosclerosis, minimum HR recorded during the 24-hour
period was the strongest predictor of severity of diffuse coronary atherosclerosis whereas
maximum HR and the total number of heart beats during the 24 hours were not related to
outcome (35). The above considerations can also explain the closer association of
cardiovascular outcomes with night-time HR compared to office HR. The studies included
in the present analysis were not specifically designed to assess the prognostic value of office
HR, and thus this variable was not recorded in a standardized fashion across the centers.
This methodological pitfall is well recognized (13,36) but it may not be the only explanation
for the different association of office HR and night-time HR with cardiovascular outcomes.
As shown by our previous results, office HR is correlated with the hemodynamic reaction
elicited by the doctor’s visit reflecting sympathetic nervous system reactivity and is thus
poorly representative of the basal HR (35). HR during sleep is more representative of the
overall hemodynamic load on the arteries and the heart. Thus a high sleeping HR would
better reflect cumulative arterial injury from mechanical stress on the arterial wall. In
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addition, persistent sympathetic over-activity may be better represented by an elevated
sleeping HR than by office HR (11). Indeed, in the present study we found strong
correlations of night-time HR with blood pressure, BMI, and metabolic abnormalities which
may be explained by a high sympathetic tone underlying elevated HR (31–34). In addition, a
high sleep HR may reflect episodes of sleep apnea that are associated with an increase in
sympathetic drive (37). The better predictive power of night-time HR compared with
daytime HR, found in the present study, parallels previous data on ambulatory blood
pressure, which showed a stronger association of blood pressure during sleep than during
waking hours with CVE (15).
Day-night HR dip
Whether night-time HR itself or the extent of the day–night dip is important for predicting
CVE remains controversial. In some studies, the day–night HR dip ratio has been found to
be significantly related to cardiovascular outcomes and to non-cardiovascular mortality
(8,11–14). However, when average ambulatory HR was included into the same model, the
day–night HR dip ratio was no longer predictive of cardiovascular outcomes in the studies
by Hansen et al. (13) and by Verdecchia et al (8), or of non-cardiovascular mortality in the
Ohasama study (12). In the present study, the association of the HR dip with CVE ceased to
be significant when average night-time systolic BP and/or the night:day ratio of systolic BP
was included in the Cox model, confirming that sleep HR itself rather than the dip ratio is
important for predicting cardiovascular morbidity, as sleep HR remained an independent
predictor when these variables were included in the model.
There is still controversy over whether the association of resting HR with cardiovascular
outcomes is similar for coronary events and stroke. Previous studies suggested that the
association of resting office HR with cardiovascular disease was mainly due to a strong
association with coronary heart disease rather than with cerebrovascular events (1,38)
although some studies found a similar impact of high office HR on coronary and
cerebrovascular mortalities (39,40). The present results obtained with ambulatory
monitoring indicate that night-time HR is an independent predictor of both coronary events
and stroke.
Limitations
Although we showed that high ambulatory HR was a predictor of CVE, the association
between high HR and CVE might be explained by reverse causality. In some patients a high
HR at night might be due to a chronic disorder that was not clinically manifest at the time of
baseline assessment. In that case, an elevated HR should be considered as an indicator of
poor physical health. In the present study, we could not adjust for important determinants of
HR, such as hemoglobin concentration, or usual physical activity. However, the association
between high HR and risk of CVE remained robust and even increased when patients who
experienced an event during the first 5 years of follow-up were eliminated, thereby
minimizing the possibility of high HR being the consequence rather than the cause of CVE.
Conclusion
We found that HR recorded during sleep with ambulatory monitoring adds prognostic
information in hypertensive patients beyond that of established ambulatory blood pressure
parameters. Thus, ambulatory HR might be considered by the practicing physician as an
additional tool for cardiovascular risk stratification. Whether lowering high ambulatory HR
in hypertensive patients can improve cardiovascular outcomes remains to be seen.
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Flow-chart of the patients from the ABP-International study selected for the present
analysis.
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Risks of cardiovascular events and 95% confidence intervals from sensitivity analyses in
which subjects who experienced a cardiovascular event within 1 year, 2 years, 3 years, or 5
years from baseline assessment were progressively excluded. Using the Cox model, the
hazard ratio is estimated by excluding all observations corresponding to survival times
before the lower time interval point. Circles indicate adjusted hazard ratios for a 10 bpm
increment in night-time heart rate. Bars indicate number of events. Numbers in the bars
indicate number of participants at risk. 1-End F/U indicates from year 1 to end of follow-up.
Risk estimates were adjusted for cohort, age, gender, smoking, diabetes, night-time systolic
blood pressure, and serum total cholesterol and serum creatinine concentrations.
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Hazard ratio of fatal and nonfatal combined cardiovascular events associated with nighttime
systolic blood pressure and night-time heart rate in 7600 hypertensive individuals stratified
by gender. The night-time systolic blood pressure is plotted along the x-axis and the scale
covers the 5th to 95th percentile interval. The night-time heart rate is represented by four
functions corresponding to levels of 55, 62, 68, and 77 beats/min (midpoints within each
heart rate quartile). Risk estimates were adjusted to 52 years of age, non-smoking, lack of
diabetes, 206 mg/dl total cholesterol, and 0.9 mg/dl serum creatinine. P-value for systolic
blood pressure <0.001, P-value for heart rate = 0.007. The interaction term between the
night-time systolic blood pressure and heart rate and gender was not significant (p=0.82).
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Table 2
AIC, Delta AIC, and BIC for the different Cox models.
Models AIC BIC
Empty Model 8146.365 Delta AIC 8146.365
Base Model* (M0) 7495.757 5.953 7526.629
Model 1 (M1):
M0 + Daytime HR
7494.129 4.325 7529.411
Model 2 (M2):
M0 + 24-hour HR
7493.146 3.342 7528.427
Model 3 (M3):
M0 + Night-time HR
7489.804 minAIC 7525.085
*
Including: Age, Gender, Diabetes, Smoking, Cholesterol, Creatinine, Systolic blood pressure
AIC indicates Akaike Information Criterion; Delta AIC is a measure of each model relative to the model with the smallest AIC (minAIC); BIC
indicates Bayesian Information Criterion; HR, heart rate.
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Table 3
Multivariable Cox analysis of risk function for fatal and nonfatal cardiovascular events in 6604 hypertensive
patients not taking beta-blockers during the follow-up.
Variable Hazard ratio (95% CI) p-value
Night-time heart rate (per 10-beat/min increase) 1.15 (1.05–1.25) .0069
Male sex 1.68 (1.38–2.03) <.001
Age (per 10-year increase) 1.71 (1.61–1.81) <.001
Smoking (yes/no*) 1.64 (1.34–2.00) <.001
Diabetes mellitus (yes/no*) 1.30 (1.02–1.66) .03
Night-time systolic BP (per 10-mm Hg increase) 1.27 (1.22–1.32) <.001
Total cholesterol (per 10-mg/dL increase) 1.04 (1.02–1.06) <.001
Serum creatinine (per 0.1-mg/dL increase) 1.08 (1.05–1.11) <.001
*
reference category;
BP indicates blood pressure; alcohol use, body mass index, and diastolic blood pressure were not accepted by the model (p>0.46).
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